抗体药物-话题@MedSci

#抗体药物#

61篇内容 | 2242人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2016162, encodeId=657d20161625c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Sci Tran Med：不止会吐口水，神兽羊驼携“天生技能”助推抗体药物进入新时代, objectType=article, longId=136071, objectId=9ccc1360e11a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ccc1360e11a, replyNumber=0, likeNumber=74, createdTime=2019-03-04, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ccc1360e11a, moduleTitle=Sci Tran Med：不止会吐口水，神兽羊驼携“天生技能”助推抗体药物进入新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ccc1360e11a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016157, encodeId=87c2201615ead, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=抗体药物研发ABC, objectType=article, longId=90138, objectId=1eeb901384c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eeb901384c, replyNumber=0, likeNumber=62, createdTime=2017-09-16, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eeb901384c, moduleTitle=抗体药物研发ABC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1eeb901384c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016160, encodeId=feda2016160a8, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Nat Protoc：上海药物所发展定点抗体药物偶联物新策略及抗体糖工程技术方案, objectType=article, longId=108336, objectId=345a108336ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=345a108336ae, replyNumber=0, likeNumber=68, createdTime=2017-11-03, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=345a108336ae, moduleTitle=Nat Protoc：上海药物所发展定点抗体药物偶联物新策略及抗体糖工程技术方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=345a108336ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016161, encodeId=15fb20161616e, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Oncotarget：新型抗体药物偶联物ENDOS/ADC有持续抗骨肉瘤作用！, objectType=article, longId=108426, objectId=8e04108426aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e04108426aa, replyNumber=0, likeNumber=61, createdTime=2018-06-22, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e04108426aa, moduleTitle=Oncotarget：新型抗体药物偶联物ENDOS/ADC有持续抗骨肉瘤作用！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e04108426aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016159, encodeId=06672016159f2, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Sci Transl Med：我国科学家设计出新型肿瘤靶向治疗策略和抗体药物, objectType=article, longId=94787, objectId=1f6994e8726, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6994e8726, replyNumber=0, likeNumber=34, createdTime=2017-10-06, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6994e8726, moduleTitle=Sci Transl Med：我国科学家设计出新型肿瘤靶向治疗策略和抗体药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6994e8726)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016158, encodeId=0fc4201615887, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=NEJM：突破！单克隆抗体药物治疗恶性白血病疗效或明显优于化学疗法, objectType=article, longId=90592, objectId=bd9f9059261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd9f9059261, replyNumber=0, likeNumber=74, createdTime=2017-06-16, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd9f9059261, moduleTitle=NEJM：突破！单克隆抗体药物治疗恶性白血病疗效或明显优于化学疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd9f9059261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016156, encodeId=61572016156c5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=全球抗体药物研发进展对中国的启示, objectType=article, longId=71532, objectId=7f06e1532d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f06e1532d1, replyNumber=0, likeNumber=76, createdTime=2017-03-07, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f06e1532d1, moduleTitle=全球抗体药物研发进展对中国的启示, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f06e1532d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016155, encodeId=7f86201615503, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=“抗体药物联合中心”在沪成立, objectType=article, longId=65054, objectId=e48b650540c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e48b650540c, replyNumber=0, likeNumber=55, createdTime=2016-09-03, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e48b650540c, moduleTitle=“抗体药物联合中心”在沪成立, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e48b650540c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016154, encodeId=95512016154c8, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Nature：新抗体药物治疗脑损伤预防长期神经退化, objectType=article, longId=53588, objectId=0e55535881b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e55535881b, replyNumber=0, likeNumber=86, createdTime=2015-09-13, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e55535881b, moduleTitle=Nature：新抗体药物治疗脑损伤预防长期神经退化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e55535881b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016151, encodeId=780d201615108, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=埃博拉抗体药物将量产？, objectType=article, longId=47791, objectId=3f1e4e79197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f1e4e79197, replyNumber=0, likeNumber=108, createdTime=2015-03-13, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f1e4e79197, moduleTitle=埃博拉抗体药物将量产？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f1e4e79197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016153, encodeId=52b72016153e5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=CLIN CANCER RES ：Anti-NaPi2b抗体药物偶联物作为非小细胞肺癌和卵巢癌治疗的临床前景, objectType=article, longId=53129, objectId=8b7d53129cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b7d53129cc, replyNumber=0, likeNumber=83, createdTime=2015-11-21, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b7d53129cc, moduleTitle=CLIN CANCER RES ：Anti-NaPi2b抗体药物偶联物作为非小细胞肺癌和卵巢癌治疗的临床前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b7d53129cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016148, encodeId=d055201614880, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Blend再获2100万美元投资助力抗体药物偶联疗法研发, objectType=article, longId=45232, objectId=624f45232c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=624f45232c4, replyNumber=0, likeNumber=80, createdTime=2015-10-30, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=624f45232c4, moduleTitle=Blend再获2100万美元投资助力抗体药物偶联疗法研发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=624f45232c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016147, encodeId=7d23201614e96, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Angiochem新型抗体药物可成功穿过血脑屏障有望治疗脑癌, objectType=article, longId=44056, objectId=a1b14405613, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1b14405613, replyNumber=0, likeNumber=75, createdTime=2015-08-30, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1b14405613, moduleTitle=Angiochem新型抗体药物可成功穿过血脑屏障有望治疗脑癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1b14405613)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016150, encodeId=cdd42016150cc, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=PCSK9抗体药物在手！辉瑞酝酿开发PCSK9小分子阻断剂药物, objectType=article, longId=45584, objectId=a925455845d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a925455845d, replyNumber=0, likeNumber=55, createdTime=2015-06-29, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a925455845d, moduleTitle=PCSK9抗体药物在手！辉瑞酝酿开发PCSK9小分子阻断剂药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a925455845d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016152, encodeId=add8201615226, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Cancer Cell：新型单克隆抗体药物或可有效克服白血病的耐药性, objectType=article, longId=49528, objectId=ffc44952814, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffc44952814, replyNumber=0, likeNumber=53, createdTime=2015-07-11, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffc44952814, moduleTitle=Cancer Cell：新型单克隆抗体药物或可有效克服白血病的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffc44952814)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016149, encodeId=071c2016149f5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Blend再获2100万美元投资助力抗体药物偶联疗法研发, objectType=article, longId=45244, objectId=2b39452449b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b39452449b, replyNumber=0, likeNumber=109, createdTime=2015-04-30, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b39452449b, moduleTitle=Blend再获2100万美元投资助力抗体药物偶联疗法研发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b39452449b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016146, encodeId=ccba2016146f0, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=复宏汉霖获得单克隆抗体药物临床批件, objectType=article, longId=32937, objectId=8e9b3293eeb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e9b3293eeb, replyNumber=0, likeNumber=85, createdTime=2014-08-04, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e9b3293eeb, moduleTitle=复宏汉霖获得单克隆抗体药物临床批件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e9b3293eeb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016145, encodeId=6eb42016145f0, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=ImmunoGen放弃其抗体药物IMGN901二期研究, objectType=article, longId=26348, objectId=9fc92634877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fc92634877, replyNumber=0, likeNumber=62, createdTime=2014-09-09, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fc92634877, moduleTitle=ImmunoGen放弃其抗体药物IMGN901二期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fc92634877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016144, encodeId=10372016144d3, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=Nature：抗体药物将重振偏头痛药物的开发, objectType=article, longId=17723, objectId=34091e7237a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34091e7237a, replyNumber=0, likeNumber=68, createdTime=2014-03-12, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34091e7237a, moduleTitle=Nature：抗体药物将重振偏头痛药物的开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34091e7237a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016142, encodeId=d0c52016142a2, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, objectTitle=J. Neurosci.：动物模型新研究表明Tau抗体药物有助于治疗阿尔茨海默病, objectType=article, longId=8301, objectId=5cc983010e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cc983010e, replyNumber=0, likeNumber=61, createdTime=2013-06-26, rootId=0, userName=zhanglin3079, userId=e6a1280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cc983010e, moduleTitle=J. Neurosci.：动物模型新研究表明Tau抗体药物有助于治疗阿尔茨海默病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cc983010e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抗体药物

2020-05-29

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Sci Tran Med：不止会吐口水，神兽羊驼携“天生技能”助推抗体药物进入新时代

2019-03-04

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

抗体药物研发ABC

2017-09-16

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Nat Protoc：上海药物所发展定点抗体药物偶联物新策略及抗体糖工程技术方案

2017-11-03

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Oncotarget：新型抗体药物偶联物ENDOS/ADC有持续抗骨肉瘤作用！

2018-06-22

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Sci Transl Med：我国科学家设计出新型肿瘤靶向治疗策略和抗体药物

2017-10-06

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

NEJM：突破！单克隆抗体药物治疗恶性白血病疗效或明显优于化学疗法

2017-06-16

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

全球抗体药物研发进展对中国的启示

2017-03-07

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

“抗体药物联合中心”在沪成立

2016-09-03

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Nature：新抗体药物治疗脑损伤预防长期神经退化

2015-09-13

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

埃博拉抗体药物将量产？

2015-03-13

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

CLIN CANCER RES ：Anti-NaPi2b抗体药物偶联物作为非小细胞肺癌和卵巢癌治疗的临床前景

2015-11-21

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Blend再获2100万美元投资助力抗体药物偶联疗法研发

2015-10-30

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Angiochem新型抗体药物可成功穿过血脑屏障有望治疗脑癌

2015-08-30

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

PCSK9抗体药物在手！辉瑞酝酿开发PCSK9小分子阻断剂药物

2015-06-29

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Cancer Cell：新型单克隆抗体药物或可有效克服白血病的耐药性

2015-07-11

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Blend再获2100万美元投资助力抗体药物偶联疗法研发

2015-04-30

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

复宏汉霖获得单克隆抗体药物临床批件

2014-08-04

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

ImmunoGen放弃其抗体药物IMGN901二期研究

2014-09-09

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

Nature：抗体药物将重振偏头痛药物的开发

2014-03-12

zhanglin3079 (审核中...)

前往app查看评论内容

#抗体药物#

J. Neurosci.：动物模型新研究表明Tau抗体药物有助于治疗阿尔茨海默病

2013-06-26

科室
- - 订阅+
  - 更多科室
工具
服务